ArticleJCEM case reports2025
Dual-mediated PTH and Osteolytic Hypercalcemia in Metastatic Endometrial Carcinoma.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercalcemia of malignancy (HCM) occurs frequently in advanced stage cancer and can be secondary to many different etiologies. This case illustrates a rare case of dual-mediated PTH and osteolytic HCM in the setting of metastatic endometrial carcinoma. The patient's hypercalcemia was refractory to initial treatment with IV hydration, calcitonin, and zoledronic acid, eventually requiring the addition of denosumab therapy and cinacalcet. After 15 days of treatment, the patient's calcium concentration returned to normal levels. Owing to elevated PTH levels, other etiologies of hypercalcemia were not initially investigated. Bone metastases, which were not observed on admission computed tomography, were incidentally identified on the technetium-99 m sestamibi scan. This case illustrates that although concurrent etiologies of hypercalcemia are uncommon, it is important to evaluate all possible contributing causes, especially in the clinical setting of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.